CRTX News and Press, Cortexyme Inc. From 09/12/21

CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern history. Success in a ...

Cortexyme (CRTX +0.1%) announces that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate COR588. The trial is a Phase 1 randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, a...

First participants dosed in clinical trial of second-generation gingipain inhibitor differentiated by novel compound properties and anticipated once daily administration Clinical advancement of pipeline delivers on commitment to bring innovation to an increasing range of ...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Casey Lynch, chief executive officer, co-founder, and chair, and C...

Gainers: Ascendis Pharma (NASDAQ:ASND) +25%, Zomedica (NYSE:ZOM) +15%, ABVC BioPharma (OTCQB:ABVC) +15%, BeyondSpring (NASDAQ:BYSI) +13%, Cortexyme (NASDAQ:CRTX) +12%. Losers: Aditxt (NASDAQ:ADTX) -29%, Quanterix (NASDAQ:QTRX) -12%, Doxim...

GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer’s pathologies Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line da...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, will participate as a featured speaker covering its pivotal Phase 2/3 GAIN...

Having reached a two-week low in the middle of the week, healthcare stocks in the S&P 500 rose two consecutive sessions to gain ~0.5% over the past five days. Yet, that was not enough to edge past the ~0.7% weekly gain in the broader index. Most healthcare stocks with the sharpest mo...

Gainers: Golden Nugget Online Gaming (NASDAQ:GNOG) +48%. Tarena International (NASDAQ:TEDU) +43%. SCWorx (NASDAQ:WORX) +32%. Select Interior Concepts (NASDAQ:SIC) +30%. Washington Prime Group (NYSE:WPG) +30%. The9 Limited (NASDAQ:NCTY) +27%. Sphere 3D (NASDAQ:ANY) +26%. Liminal BioSciences (N...

GAIN Trial top-line data for disease modification in Alzheimer’s expected by mid-November 2021 Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021 Current cash position sufficient to fund operations through 2023 ...